Cartesian Therapeutics, Inc. announced its plans to transition its corporate headquarters to Frederick, Maryland. The approximately 20,000 square foot current good manufacturing practice (cGMP) compliant facility has clinical and commercial manufacturing scale capabilities designed to support the Company's maturing pipeline of innovative mRNA cell therapies for the treatment of autoimmune diseases. Cartesian's internally manufactured portfolio of mRNA cell therapies is purposefully designed to expand the reach of cell therapy to autoimmunity with product candidates that have the potential to be administered conveniently and safely in an outpatient setting without lymphodepletion chemotherapy.

Topline data from the Phase 2b study of Descartes-08 in myasthenia gravis (MG) is expected in mid-2024.